ArticleDermatology reports2025
Isolated cutaneous myeloid sarcoma preceding acute myeloid leukemia: a case report and literature review.
Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated cutaneous myeloid sarcoma (icMS) and aleukemic leukemia cutis (ALC) are cutaneous extramedullary manifestations of leukemia in which leukemic cells infiltrate the skin before they can be identified either in the peripheral blood or in the bone marrow. We report the case of a 67-year-old patient who presented with a rapidly developing cutaneous tumor and scaly, erythematous- squamous plaques. Isolated cutaneous myeloid sarcoma was diagnosed, which rapidly progressed to terminal-stage acute myeloid leukemia (AML). To highlight the disease characteristics of the adult-onset icMS and ALC cases that preceded AML, we additionally compiled the pertinent literature of case reports of these rare conditions. We identified 15 previously published icMS/ALC cases with adequately detailed clinical data descriptions. We could confirm medical experience that icMS/ALC patients have a worse overall prognosis. Moreover, we could identify FAB-M5 AML subtype as a significant adverse prognosticator in these patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.